

Middlesex University Research Repository

An open access repository of

Middlesex University research

<http://eprints.mdx.ac.uk>

Foroozanfard, Fatemeh, Asemi, Zatollah, Bazarganipour, Fatemeh, Taghavi, Seyed Abdolvahab, Allan, Helen T. ORCID logoORCID: <https://orcid.org/0000-0001-9391-0385> and Aramesh, Shahintaj (2020) Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study. *Gynecological Endocrinology*, 36 (1) . pp. 61-65. ISSN 0951-3590 [Article] (doi:10.1080/09513590.2019.1631278)

Final accepted version (with author's formatting)

This version is available at: <https://eprints.mdx.ac.uk/27004/>

Copyright:

Middlesex University Research Repository makes the University's research available electronically.

Copyright and moral rights to this work are retained by the author and/or other copyright owners unless otherwise stated. The work is supplied on the understanding that any use for commercial gain is strictly forbidden. A copy may be downloaded for personal, non-commercial, research or study without prior permission and without charge.

Works, including theses and research projects, may not be reproduced in any format or medium, or extensive quotations taken from them, or their content changed in any way, without first obtaining permission in writing from the copyright holder(s). They may not be sold or exploited commercially in any format or medium without the prior written permission of the copyright holder(s).

Full bibliographic details must be given when referring to, or quoting from full items including the author's name, the title of the work, publication details where relevant (place, publisher, date), pagination, and for theses or dissertations the awarding institution, the degree type awarded, and the date of the award.

If you believe that any material held in the repository infringes copyright law, please contact the Repository Team at Middlesex University via the following email address:

eprints@mdx.ac.uk

The item will be removed from the repository while any claim is being investigated.

See also repository copyright: re-use policy: <http://eprints.mdx.ac.uk/policies.html#copy>

**Pregnancy, childbirth and neonatal outcomes in women with different
phenotypes of polycystic ovary syndrome and healthy women: a prospective
cohort study**

Fatemeh Foroozanfard¹, Zatollah Asemi², Fatemeh Bazarganipour³, Seyed Abdolvahab Taghavi³,
Helen Allan⁴, Shahintaj Aramesh^{3*}

¹ *Gametogenesis Research Center, Kashan University of Medical Sciences, Kashan, Iran*

² *Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of
Medical Sciences, Kashan, I.R. Iran*

³ *Department of Gynecology and Obstetrics, Yasuj Medical University, Yasuj, Iran*

⁴ *Centre for Critical Research in Nursing & Midwifery, School of Health & Education,
Middlesex University, London*

* Corresponding author: Shahintaj Aramesh, email: Sh.aramesh123@yahoo.com

The co-authors' email addresses:

1. Fatemeh Foroozanfard

Foroozanfard.fatemeh@gmail.com

2. Zatollah Asemi

Asemi_r@yahoo.com

3. Fatemeh Bazarganipour

f.bazarganipour@gmail.com

4. Seyed Abdolvahab Taghavi

23 Vahab.taghavi@gmail.com

24 5. Helen Allan

25 h.allan@mdx.ac.uk

26 6. Shahintaj Aramesh

27 Sh.aramesh123@yahoo.com

28

29 **Number of words (Text): 2090**

30 **Number of words (Abstract): 196**

31 **Number of Tables: 3**

32

Abstract

Aims: The aim of this study was to compare the complications of pregnancy, childbirth and neonatal in women with different forms of polycystic ovary syndrome (PCOS) with healthy women.

Methods: A prospective study from the beginning to the end of pregnancy for 41 pregnant women with PCOS (case) and 49 healthy pregnant women (control) was completed. Based on the presence or absence of menstrual dysfunction (M), hyperandrogenism (HA) and polycystic ovaries (PCO) on ultrasound, the PCOS (case) group were divided into three phenotypes (HA + PCO (n=22), M + PCO (n=9), HA + M + PCO (n=10).

Result: Pre-eclampsia, gestational diabetes and lower birth weight among newborns were significantly higher in the PCOS case group compared to the control group especially in the phenotype HA + M + PCO ($P<0.05$). High BMI ($\beta=2.40$; $P=0.03$) was the strongest predictor of pre-eclampsia in patients with PCOS. High androgen levels (free androgen index) ($\beta=13.71$, 3.02 ; $P<0.05$), was the strongest predictor of developing diabetes during pregnancy and reduced birth weight baby, respectively.

Conclusion: The results of the present study suggest that PCOS is a risk factor for adverse pregnancy and neonatal outcomes including gestational diabetes, pre-eclampsia and reduced weight babies.

Keywords: polycystic ovary syndrome, pregnancy complications, neonatal complications, phenotype.

Introduction

Polycystic ovary syndrome (PCOS) is a common and complex endocrine disorder that affects women of reproductive age (1). The Rotterdam criteria suggest that there are three detectable phenotypes in women presenting with PCOS symptoms: anovulation/menstrual irregularities with polycystic ovary with ultrasound (M + PCO), hyperandrogenism with polycystic ovary with ultrasound (HA + PCO) and hyperandrogenism with anovulation/menstrual irregularities and polycystic ovary (M + HA + PCO). The prevalence of PCOS in the studies was estimated 2.2-26% in developed countries (2-5). Complications associated with polycystic ovary syndrome can occur across the life span for women (6). In this study, we considered complications and outcomes associated with pregnancy, childbirth and neonatal period. Prospective and retrospective studies have been reported PCOS as a risk factor for increased incidence of pregnancy complications (7-9). Pregnancy complications in the first trimester in women with PCOS include hyperemesis gravidarum, abortion and fetal abnormalities (10-12).

Pregnant women with PCOS are at increased risk of gestational diabetes as pregnancy is one of the predisposing factors to increased insulin resistance that may result in gestational diabetes during pregnancy. In addition, insulin resistance is higher in women with PCOS who are overweight (25-70% of women with PCOS has insulin resistance). Further potential risks include gestational diabetes, preeclampsia, gestational hypertension, premature birth, mortality and an increased risk of hospitalization in the intensive care unit for newborns in pregnant patients with PCOS (13). In the only study to assess pregnancy and neonatal outcomes in women with PCOS with different phenotypes (n=97) compared to healthy pregnant women (n=73), Palomba et al. reported significant differences in the prevalence of abortion, gestational hypertension,

gestational diabetes, pre-delivery bleeding between the phenotypes of PCOS and control groups, respectively. In Palomba et al.(14) study, there were no significant differences between groups in terms of incidence of fetal malformations, placental abruption and Apgar score. And in a meta-analysis, Qin et al.(15), suggested that the effects of pregnancy and neonatal outcomes among phenotypes of PCOS are unknown and requires further studies in this regard.

Given the prevalence of PCOS in Iran (1.7-6.14%) and the lack of adequate information on pregnancy and neonatal outcomes in women with different phenotypes of PCOS, this study aimed to evaluate the results of pregnancy, childbirth and neonatal outcomes in women with different PCOS phenotypes compared to healthy pregnant women.

Methods

Design and data collection

The present study is a prospective cohort study using convenience sampling. In this study exposure was having PCOS and not exposure was no PCOS for investigate how adverse obstetric outcomes vary. Therefore, the exposure group included women with PCOS referred to an infertility clinic in Shahid Beheshti hospital in Kashan, Isfahan, Iran from April 2014 to April 2016. This is the only referral clinic in Kashan. The non exposure group comprised healthy women who had been referred to this clinic because of male factor infertility. After presenting the purpose of the study to suitable participants who met the inclusion criteria, a written consent was obtained from each volunteer who were asked to complete the three measures.

Inclusion criteria were Desire to participate in the study, being 15–40 years of age, Married, Absence of non-classic adrenal hyperplasia, thyroid dysfunction, hyperprolactinemia, Non-smoking, No problems in speaking or listening, Iranian, First pregnancy, Spontaneous pregnancy, Not having uterus malformations, Not having chronic diseases, Having two of the following Rotterdam diagnostic criteria:

- 1) Polycystic ovaries visualized on ultrasound scan (presence of 12 follicles or more in one or both ovaries and/or increased ovarian volume i.e., >10 ml),

104 2) clinical signs of hyperandrogenism (hirsutism score based on hirsutism score greater than 7 or
105 obvious acne) ,
106 3) having an interval between menstrual periods >35 days and/or amenorrhea, defined as the
107 absence of vaginal bleeding for at least 6 months (i.e. 199 days).

108 According to Palomba et al.(14), P1:46.2%, P2:85.5%, $\alpha=0.05$ and $\beta=0.20$, sample size was
109 estimated at 40 couples per group.

110 Hormonal profiles were sought in both groups before pregnancy. The participants were followed
111 from 7 weeks (6-10 weeks) of pregnancy until after delivery. The pregnancy visit intervals were
112 according to Iran Ministry of Health guideline.

113

114 **Measures**

1151. Menstrual history: women were asked about the interval of two menstrual cycles in the last 12
116 months; their menstrual cycles were classified as following: <21 days, 21-34-34-60, >199 days
117 and irregular.

1182. BMI: this variable was estimated by dividing each patient's weight by height² (Kg/m²).

1193. Hirsutism: hirsutism scoring was based on the Gallway scale (1961). Hutch et al.(16) modified
120 this scoring system and limited it to 9 androgen sensitive areas each area based on the growth of
121 terminal hair scored from 0-4 (17). A score of 7 or more indicated hirsutism .

1224. Acne: Global Acne Grading Scale (GAGS) was assessed to measure acne. This scale considers
123 six areas of the face, chest and upper back to measure the level of involvement, distribution,
124 density and pilosebaceous units. Each of the six areas scores from 0-4 with the most severe
125 lesion in each area determining the score of that area; the score of each region is multiplied by
126 the factor score. The factor score is calculated according to the area involved: forehead: 2; left

127 and right cheek: 2; nose: 1; chin: 1; chest and upper back: 3. The total score is obtained by
128 multiplying the factor score by total score of involved area (18).

1295. Evaluation of cervical incompetence: transvaginal ultrasound from 16-24 weeks' gestation was
130 performed by a gynecologist. The mean cervical length from 16-24 weeks of pregnancy is 25
131 mm. Cervical length < 25 mm does not indicate cervical incompetence but it is a risk factor for
132 adverse pregnancy outcomes. Cervical incompetence indicates preterm delivery due to passive
133 dilation of the uterine cervix. Cervical length < 25 mm is an indication for cerclage placement in
134 a population of pregnant women with a history of preterm delivery. In this study we considered
1356. cervical length <25 mm as cervical incompetence and cervical length >25 mm as not having
136 cervical incompetence (19).

1377. Pregnancy-Unique Quantification of Emesis/Nausea (PUQE) Index: The three PUQE questions
138 each have a rating from 1–5, thus the composite sum ranged from 3–15. A score between 3–6
139 points was defined as mild, 7–12 points as moderate and scores ≥ 13 points was classified as
140 severe nausea and vomiting. Reliability and validity of the questionnaire is approved (20).

141

142 **Laboratory measure**

143 An overnight 8-12 hours fasting venous blood sample was obtained from each patient. Serum
144 total testosterone (TT), sex hormone-binding globulin (SHBG), follicle-stimulating hormone
145 (FSH), and luteinizing hormone (LH), thyroid stimulating hormone (TSH) and prolactin (PRL)
146 were concomitantly assessed in all participants by ELISA (DRG Instruments GmbH, Marburg,
147 Germany). TT and SHBG were used to calculate the free androgen index (FAI). FAI was
148 estimated as $TT \text{ (nmol/l)} / SHBG \text{ (nmol/l)} \times 100$. Except for amenorrhoeic women, all laboratory
149 determinations were performed in the early follicular phase (3-day menstruation) of the cycle. In

amenorrhoeic women, after roll out of pregnancy the all laboratory determinations were performed.

What does this mean? Because amenorrhea may be related to pregnancy that the hormonal profile will be different with non pregnancy.

Data analysis

In the present study, we used descriptive and analytic statistics using SPSS 21. Data are presented as mean (standard deviation) for quantitative variable and n (%) for qualitative variable. The normality of the distributions was tested using the Kolmogorov-Smirnov test. In order to make comparison between groups, a *t*-test was used for quantitative and Mann-Whitney test for ordinal variables. For comparison between phenotypes of PCOS, the ANOVA test was used for quantitative and Kruskal-Wallis test for ordinal variables. Linear regression (for neonate weight) and logistic regression (for preeclampsia and diabetes) were used to determine the most important predictors.

Univariate and stepwise multiple logistic regression analysis were used to evaluated risk factors associated with above outcomes (significant differences related to these outcome between different phenotypes of PCOS). The analysis of risk factors was concluded in two steps. All the socioeconomic and characteristics of patients presented in Table 1 were tested one by one in separate, univariate analysis. Secondly, all statistically significant variables in the univariate analysis were tested using multivariable logistic regression analysis. Significant variable were entered in a stepwise manner. Results from the final model are presented as odd ratio with 95% confidence interval. The information entered to the regression models was limited to women

with PCOS (significant differences related to these outcomes between different phenotypes of PCOS). A significance level of 0.05 was acceptable.

Ethics

The ethics committee of Kashan University of Medical Sciences approved the present study. All women gave written inform consent.

Findings

1. Baseline characterize of participant

Demographic and reproductive characteristics of participants are presented in **Table 1**. The results show that significant differences between PCOS and control groups in terms of acne score (3.62 ± 4.80 vs. 1.82 ± 4.08 ; $P=0.05$), hirsutism score (3.18 ± 4.25 vs. 1 ± 2.31 ; $P=0.003$), irregularities menses ($P<0.001$), testosterone levels (1.02 ± 0.52 vs. 0.65 ± 0.43 ; $P=0.05$), SHBG (146.66 ± 2.29 vs. 120.50 ± 3.24 ; $P=0.05$), FAI (10.21 ± 34.45 vs. 4.71 ± 1.70 ; $P=0.02$) were observed.

2. Obstetric and neonatal status between PCOS and control patients

Table 2 compares pregnancy, delivery and neonatal outcomes between the two groups. Results show that significant differences between the two groups in the incidence of pre-eclampsia ($P=0.05$), gestational diabetes ($P=0.05$) and birth weight ($P=0.05$) were observed. It should be noted that there are any IUGR and LGA in two groups.

3. Obstetric and neonatal outcome between different phenotypes of PCOS

Results of **Table 3** show the comparison of pregnancy, delivery and neonatal outcomes among women with different PCOS phenotypes. Significant differences related to pre-eclampsia ($P=0.05$), gestational diabetes ($P=0.05$) and birth weight ($P=0.05$) between the three PCOS phenotype were observed. HA + M + PCO phenotype have a higher frequency of pre-eclampsia and gestational diabetes and lower birth weight of neonates than other phenotypes respectively. It should be noted that there are any IUGR, LGA and PROM in any of the three groups.

4. Predictive factors of obstetric and neonatal outcome

The regression results showed that high BMI ($\beta=2.40$; $CI=1.02-1.58$) and increased FAI ($\beta=13.71$; $CI=13.71-76.07$) were the strongest predictors of pre-eclampsia and diabetes in patients with PCOS (Data not shown). Moreover, the regression results show that the increase in FAI ($\beta=3.02$; $CI=-20.86, -66.91$) was the strongest predictor of weight babies were born to mothers with PCOS.

Discussion

This study aimed to assess the pregnancy, delivery and neonatal outcomes in women with PCOS compared to controls. Results of the study show a higher incidence of pre-eclampsia and diabetes, and lower weight infants in women with PCOS compared to the control group. Similar to our findings, in a study conducted by Bjercke et al.(9), the results showed that the prevalence of pre-eclampsia was higher significantly in women with PCOS (13.5%) compared with the control group (7%). The prevalence of gestational diabetes in women with PCOS (7.7%) was higher compared with control (0.6%). The results from Roos et al.(21) also show significantly increased prevalence of gestational diabetes and pre-eclampsia in women with PCOS compared

with the control group. Although the study of Palomba et al.(14), the prevalence of gestational diabetes in PCOS lower than the control group and M + PCO phenotype of PCOS had the highest prevalence. Roos et al. and Bjerkke et al. not cited in literature review or background: this was cited in background as whole.

Despite the high prevalence of gestational diabetes mellitus in patients with PCOS compared to control in the study, the fetal macrosomia was expected. But, the birth weight in PCOS was less than the control group especially phenotype HA + M + PCO. This finding may be due to the incompetence of the placenta in these women who tend to have a high incidence of pre-eclampsia. In a recent review, Qin et al.(15) have proposed there is no definite risk factor for adverse pregnancy complications in women with PCOS identified as yet. But, Veltman-Verhulst et al.(22) found that low level of SHBG predicts GDM in women with PCOS. It has been suggested that FAI is a better and more accurate indicator to measure abnormal androgen level (23). In the present study, testosterone and SHBG levels were evaluated to assess the FAI. The results showed that the FAI level was the strongest predictor of gestational diabetes and weight loss of babies in patients with PCOS.

Previous studies have shown that insulin resistance in PCOS could play a role in the pathogenesis of pre-eclampsia (9). Although in the current study, the level of insulin resistance was not measured, the relationship between insulin resistance and androgen levels in non-pregnant women with PCOS has already been demonstrated (24). Introducing higher BMI as the strongest predictor of pre-eclampsia in the present study and increased levels of androgens in fatty status is approved this finding. Moreover, in regard to the high incidence of the above outcomes in HA+M+PCO phenotypes of PCOS, it should be noted that previous studies have

shown that androgen levels in this phenotype of PCOS women was higher than other phenotypes and more prone to metabolic complications. In other words, biochemical hyperandrogenism plays an essential role in metabolic changes and non-androgenic phenotypes of PCOS are at a reduced risk of metabolic adverse effects than other phenotypes (25-26).

This study is not without limitations. Participants were selected using a simple sampling method. The present study is limited to the women recruited from the only referral hospital for infertility on Kashan, Isfahan, Iran; this may limit the generalizability of our findings. However, it should be noted that the women in previous studies were also undergoing infertility treatments that had different endocrine characteristics and pregnancy outcomes. The merit of the present study is that all women had a spontaneous pregnancy. Moreover, PCOS diagnosis was confirmed by a physician experienced in the clinic. All women were first gravidity.

Conclusions

The results of the present study suggest that PCOS is a risk factor for adverse outcomes in pregnancy and neonatal including GDM, pre-eclampsia and weight of newborn. These results were significantly higher in phenotype HA + M + PCO than other phenotypes. Further prospective studies with bigger sample and different Iranian population are needed to confirm the findings.

260 **Competing interests**

261 The authors declare no conflict of interest.

262

263 **Funding**

264 The research grant provided by Research Deputy of Kashan University of Medical Science
265 (KUMS).

266

References

1. Azziz R. Androgen excess is the key element in polycystic ovary syndrome. *Fertil Steril*. [Research Support, U S Gov't, P H S Review]. 2003;80(2):252-4.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *J Clin Endocrinol Metab*. 1998 Sep;83(9):3078-82.
3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. *J Clin Endocrinol Metab*. 2000 Jul;85(7):2434-8.
4. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. *Clin Endocrinol*. [Research Support, Non-U S Gov't]. 1999;51(6):779-86.
5. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. *J Clin Endocrinol Metab*. 1999;84(11):4006-11.
6. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. *Lancet*. [Review]. 2007;370(9588):685-97.
7. Wortsman J, de Angeles S, Futterweit W, Singh KB, Kaufmann RC. Gestational diabetes and neonatal macrosomia in the polycystic ovary syndrome. *J Reprod Med*. [Clinical Trial Multicenter Study Research Support, Non-U S Gov't]. 1991;36(9):659-61.
8. Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. *Hum Reprod*. [Research Support, Non-U S Gov't]. 2003;18(7):1438-41.
9. Bjorcke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. *Gynecol Obstet Invest*. 2002;54(2):94-8.
10. Verberg MF, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. *Hum Reprod Update*. [Review]. 2005;11(5):527-39.

297 11. Orio F, Jr., Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, et al. The
 298 increase of leukocytes as a new putative marker of low-grade chronic inflammation and early
 299 cardiovascular risk in polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2005;90(1):2-5.

300 12. Sugiura-Ogasawara M, Sato T, Suzumori N, Kitaori T, Kumagai K, Ozaki Y. The
 301 polycystic ovary syndrome does not predict further miscarriage in Japanese couples experiencing
 302 recurrent miscarriages. *Am J Reprod Immunol.* [Research Support, Non-U S Gov't].
 303 2009;61(1):62-7.

304 13. Carlsen SM, Vanky E. Metformin influence on hormone levels at birth, in PCOS mothers
 305 and their newborns. *Hum Reprod.* [Randomized Controlled Trial
 306 Research Support, Non-U S Gov't]. 2010;25(3):786-90.

307 14. Palomba S, Falbo A, Russo T, Tolino A, Orio F, Zullo F. Pregnancy in women with
 308 polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and
 309 neonatal outcomes. *Fertil Steril.* 2010;94(5):1805-11.

310 15. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in
 311 women with polycystic ovary syndrome: a systematic review and meta-analysis. *Reprod Biol*
 312 *Endocrinol.* [Meta-Analysis
 313 Review]. 2013;11(56):1477-7827.

314 16. Baweja R, Bhattacharya SK, Choudhury SD, Krishna U, Manuel M, Phillips FS, et al.
 315 Indian Council of Medical Research. Task Force on Hormonal Contraception: Phase II
 316 randomized clinical trial with norethisterone oenanthate 50 mg alone and in combination with 5
 317 mg or 2.5 mg of either estradiol valerate or cypionate as a monthly injectable contraceptive.
 318 Contraception. [Clinical Trial
 319 Comparative Study
 320 Randomized Controlled Trial
 321 Research Support, Non-U.S. Gov't]. 1985;32(4):383-94.

322 17. Ferrimanm D, Gallwey JD. Clinical assessment of body hair growth in women. *J Clin*
 323 *Endocrinol Metab.* 1961;21:1440-7.

324 18. Lever WF, Schaumburg-Lever G. Acne vulgaris. *Histopatbology of the Skin.* 7th edn
 325 Philadelphia: JB Lippincott. 1990:218-9.

19. Owen J, Szychowski JM, Hankins G, Iams JD, Sheffield JS, Perez-Delboy A, et al. Does Mid-trimester Cervical Length \geq 25 mm Predict Preterm Birth in High-Risk Women? American journal of obstetrics and gynecology. 2010;203(4):393.e1-e5.
20. Koren G, Boskovic R, Hard M, Maltepe C, Navioz Y, Einarson A. Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am J Obstet Gynecol. [Research Support, Non-U S Gov't]. 2002;186(5 Suppl Understanding):S228-31.
21. Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. Bmj. [Research Support, Non-U S Gov't]. 2011;13(343).
22. Veltman-Verhulst SM, van Haeften TW, Eijkemans MJ, de Valk HW, Fauser BC, Goverde AJ. Sex hormone-binding globulin concentrations before conception as a predictor for gestational diabetes in women with polycystic ovary syndrome. Hum Reprod. [Clinical Trial Research Support, Non-U S Gov't]. 2010;25(12):3123-8.
23. Vankrieken L. Testosterone and the free androgen index. Diagnostic Products Corporation. 1997.
24. Svendsen PF, Madsbad S, Nilas L. The insulin-resistant phenotype of polycystic ovary syndrome. Fertil Steril. 2010;94(3):1052-8.
25. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril. 2007;88(5):1389-95.
26. Chang WY, Knochelhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. [Comparative Study Research Support, N I H , Extramural Research Support, U S Gov't, P H S]. 2005;83(6):1717-23.

Table 1. Demographic and clinical characterizes in participants

Variable		PCOS (n=43)			Non PCOS (n=47)	P value§
		HA+PCO (n=22)	M+PCO (n=9)	M+HA+PCO (n=10)		
Age **		24.30±6.25	24.41±3.49	25.03±9.31	25.53±4.14	0.56
Education **		12.69±3.05	11.63±4.11	11.04±4.92	13.19±3.04	0.60
Acne score**		6.93±1.38	6.58±2.30	6.83±1.10	1.82±4.08	0.05£¥
Hirsutism score**		11.03±0.31	11.17±0.01	9.40±0.18	1±2.21	0.003£¥
BMI (kg/m ²)**		25.80±6.53	23.43±7.11	24.42±2.34	24.34±3.99	0.09
Menstruation *	<21 day	2(3.77)	5(7.57)	4(7.01)	1(2.1)	<0.001£¥
	21-35 day	22(41.50)	28(42.42)	30(52.63)	44 (93.6)	
	35-60 day	15(28.30)	18(27.27)	9(15.78)	2 (4.3)	
	190 day	6(11.32)	8(12.12)	9(15.78)	-	
	Variable	8(15.09)	7(10.60)	5(8.77)	-	
Systolic blood pressure in 6-10 weeks of pregnancy**		117.16±10.67	116.71±20.78	116.16±10.67	115.42±12.71	0.76
Diastolic blood pressure in 6-10 weeks of pregnancy**		76.39±8.33	71.24±8.74	73.37±8.43	75.42±8.58	0.25
FBS in 6-10 weeks of pregnancy**		86.52±8.12	87.62±9.11	88.12±7.21	87.40±7.61	0.93
Hb in 6-10 weeks of pregnancy**		12.31± 0.59	12.03± 0.98	12.59± 0.89	12.68±0.99	0.66
HCT in 6-10 weeks of pregnancy**		36.22±2.92	35.12±3.76	36.82±3.33	37.78±2.91	0.17
Testosterone (nmol/L)**		1.43±0.12	1.0±0.12	1.02±0.52	0.65±0.45	0.05£¥
SHBG (nmol/L)**		153.61±2.12	134.61±2.1	126.66±2.2	120.50±3.34	0.05£¥

			9		
PRL(IU/l) **	54.11±31.10	55.81±91.1 1	56.71±26.1 8	47.93±20.83	0.71
FAI**	10.21±34.45	8.11±61.41	8.22±37.14	4.71±1.70	0.02£¥
TSH(IU/l) **	2.90±0.2	2.37±0.49	2.67±0.92	2.61±1.78	0.29
LH (IU/l) **	74.65± 2.52	77.84± 3.34	78.69± 3.21	73.84±1.63	0.80
FSH (IU/l) **	58.21±26.18	56.71±9.76	53.82±32.1 2	47.93±20.83	0.34

*N (%), ** Mean±SD

*ANOVA

**kruskal wallis test

§ P<0.05 between PCOS and Non PCOS phenotype;£ P<0.05 between H+PCO and H+PCO+M phenotype; €

P<0.05 between H+PCO and M+PCO phenotype;¥ P<0.05 between H+PCO+M and M+PCO phenotype

Table 2. Comparison the pregnancy, childbirth and neonatal outcomes between PCOS and control groups

Variable		PCOS (n=43)	Control (n=47)	P value
Abortion *		1(2.3)	1(2.1)	0.91
Malformation *		1(2.3)	2(4.3)	0.61
PIH*		3(7)	1(2.1)	0.98
Pre-eclampsia *		4(9.3)	1(2.1)	0.05
GDM*		8(18.6)	6(12.8)	0.05
Amniotic fluid in 32-34 weeks of pregnancy*		3(7)	0	0.06
Abruption *		3(7)	3(6.4)	0.83
Preterm labor *		6(14)	7(14.9)	0.97
PROM*		-	2(4.3)	0.18
PUQE in 6-10 weeks of pregnancy *	Moderate	41(95.3)	44(93.6)	0.36
	Severe	2(4.65)	3(6.4)	
PUQE in 16-20 weeks of pregnancy*	Moderate	40(93)	46(97.9)	0.28
	Severe	2(4.65)	-	
Delivery type*	NVD	23(53.5)	18(38.3)	0.09
	C/S	20(46.51)	29(61.70)	
Anthropometric	Weight	3065.50±0.49	3124.13±0.11	0.05
characterize of neonate**	Height	45.96±2.53	48.43±2.11	0.30
	Head circumference	33.91±1.56	34.54±1.74	0.29
Neonate's Apgar in 1 minute **		8.97±0.16	8.86±0.34	0.10
Neonate's Apgar in 5 minute**		10±0	9.95±0.20	0.20

*N (%), ** Mean±SD

Table 3. Comparison the pregnancy, childbirth and neonatal outcomes among different phenotypes of PCOS

Variable		HA+PCO (n=22)	M+PCO (n=9)	M+HA+PCO (n=10)	P value
Abortion *		-	1(11)	-	0.20
Malformation *		-	-	1(10)	0.20
PIH*		1(4)	1(11)	2(20)	
Preeclampsia*		2(9)	1(11)	4(40)	0.05
GDM*		2(9)	1(11)	3(30)	0.05
Abnormal amniotic fluid in 32-34 weeks of pregnancy*		1(4)	1(11)	2(20)	0.16
Abruption *		2(9)	1(11)	-	0.49
Preterm labor *		2(9)	3(33.33)	1(10)	0.85
PUQE in 6-10 weeks of pregnancy *	Moderate	16(70)	6(66.66)	9(90)	0.20
	Severe	-	-	1(10)	
PUQE in 16-20 weeks of pregnancy*	Mild	-	-	9(90)	0.05
	Moderate	16(70)	5(55.55)	1(10)	
Delivery type*	NVD	8(36.36)	4(44.44)	6(60)	0.81
	C/S	14(63.63)	5(55.55)	4(40)	
Anthropometric characterize of neonate**	Weight	2978.66±22.31	2971.87±87.15	2280±0.52	0.05
	Height	48.64±3.34	48.26±1.43	50.61±1.93	0.40
	Head circumference	33.82±2.05	33.87±1.36	34.11±1.13	0.60
Neonate's Apgar in 1 minute **		9±0	8.93±0.25	9±0	0.49
Neonate's Apgar in 5 minute**		10	10	10	-

*N (%), ** Mean±SD